新生儿研究网络对缺氧缺血性脑病的神经保护作用。
Neuroprotection for hypoxic-ischemic encephalopathy: Contributions from the neonatal research network.
机构信息
Division of Neonatal & Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.
Division of Neonatal-Perinatal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Semin Perinatol. 2022 Nov;46(7):151639. doi: 10.1016/j.semperi.2022.151639. Epub 2022 Jun 10.
Therapeutic hypothermia (TH) is now well established as the standard of care treatment for moderate to severe neonatal encephalopathy secondary to perinatal hypoxic ischemic encephalopathy (HIE) in infants ≥36 weeks gestation in high income countries. The Neonatal Research Network (NRN) contributed greatly to the study of TH as a neuroprotectant with three trials now completed in infants ≥36 weeks gestation and the only large randomized-controlled trial of TH in preterm infants now in the follow-up phase. Data from the first NRN TH trial combined with data from other large trials of TH affirm the safety and neuroprotective qualities of TH and highlight the importance of providing TH to all infants who qualify. In this review we will highlight the findings of the three NRN trials of TH in the term infant population and the secondary analyses that continue to inform the care of patients with HIE.
治疗性低体温（therapeutic hypothermia，TH）现已被确立为中重度围产期缺氧缺血性脑病（hypoxic ischemic encephalopathy，HIE）所致足月新生儿的标准治疗方法。新生儿研究网络（Neonatal Research Network，NRN）在 TH 作为神经保护剂的研究中做出了重要贡献，目前已经完成了三项针对≥36 孕周婴儿的试验，以及唯一一项针对早产儿的大型随机对照试验目前正在随访阶段。来自 NRN 首个 TH 试验的数据与其他 TH 大型试验的数据相结合，证实了 TH 的安全性和神经保护作用，并强调了为所有符合条件的婴儿提供 TH 的重要性。在本综述中，我们将重点介绍 NRN 针对足月婴儿人群开展的三项 TH 试验的结果，以及继续为 HIE 患者提供治疗的辅助分析。
Zotero 插件